KYTX News & Events

Kyverna Therapeutics announced positive longer-term follow-up data from the Phase 2 portion of its registrational KYSA-6 trial of miv-cel in patients with generalized myasthenia gravis. The data will be presented today during an oral presentation at the American Academy of Neurology Annual Meeting in Chicago. The updated data demonstrate deep and durable clinical responses across all key clinical outcome measures with sustained benefit observed out to one year following a single dose of miv-cel. Further, miv-cel was well-tolerated. Efficacy highlights from the updated Phase 2 trial following a single dose of miv-cel are as follows: 100% of patients achieved clinically sustained reductions in MG-ADL and QMG scores from baseline, regardless of prior biologic exposure and at deeper levels observed compared to prior interim analysis. 100% of patients were free of nonsteroidal immunosuppressants, high-dose steroids (greater than10mg), and FcRn and complement inhibitors through Week 24. Additionally, Miv-cel demonstrated a well-tolerated safety profile supporting the potential for outpatient administration

Kyverna Therapeutics files $300M mixed securities shelf

Kyverna reported $279.3M in cash, cash equivalents, and marketable securities as of December 31, 2025. The company expects to have a cash runway into 2028, funding its SPS BLA filing and commercial launch and its Phase 3 gMG trial. "We continue to cement our leadership in autoimmune CAR T supported by our unique construct and a growing body of transformative clinical data that reinforces miv-cel's differentiated profile," said Warner Biddle, CEO of Kyverna Therapeutics. "We are advancing the first CAR T for stiff person syndrome, a serious and debilitating disease with no FDA-approved treatments, representing a significant unmet need and meaningful commercial opportunity. Our market entry will establish the foundation for our neuroimmunology franchise with expansion into generalized myasthenia gravis and potentially other indications, such as progressive multiple sclerosis, where miv-cel has shown promising clinical benefit."

Kyverna Therapeutics announced the appointments of Sravan Emany and Andrew Miller, Ph.D. to its Board of Directors. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped down from the Board. Emany currently serves as the CFO of Beam Therapeutics. Most recently, Dr. Miller was the Founder and President of R&D at Karuna Therapeutics.